Skip to main content
Vivesto logo

Vivesto — Investor Relations & Filings

Ticker · VIVE ISIN · SE0000722365 LEI · 5493003TZPR4B7QO9L49 ST Manufacturing
Open in API
Filings indexed 1,069 across all filing types
Latest filing 2019-07-02 Board/Management Inform…
Country SE Sweden
Listing ST VIVE

About Vivesto

https://www.vivesto.com/en/

Vivesto is a specialty pharmaceutical company focused on drug development in oncology. The company aims to provide new therapeutic options for patients suffering from hard-to-treat cancers where significant medical needs exist. Its research and development efforts are centered on creating innovative treatments and enhancing the intravenous delivery of established and novel drugs. The company's lead product is Apealea, a formulation of the cancer drug paclitaxel.

Recent filings

Filing Released Lang Actions
Oasmia appoints Scientific Advisory Board
Board/Management Information Classification · 99% confidence The document is a press release dated July 2, 2019, announcing the appointment of key members to Oasmia's Scientific Advisory Board. This type of announcement concerns changes in the company's advisory structure, which falls under the scope of management or board-related information, but more specifically relates to the scientific/R&D leadership structure. Reviewing the definitions, 'Board/Management Information (MANG)' covers 'Announcement of changes in the company's board of directors or senior management.' While an advisory board isn't strictly 'management' or 'directors,' in the context of these specific codes, announcements regarding key leadership appointments (especially scientific leadership which guides R&D strategy) are best categorized under MANG, as it relates to the governance and strategic direction provided by senior personnel/bodies. It is not an ER, CT, or a formal regulatory filing like 10-K or AR. It is a specific announcement about key personnel appointments.
2019-07-02 English
Oasmia announces change of CEO
Board/Management Information Classification · 100% confidence The document announces the appointment of a new CEO, Sven Rohmann, and details changes in the management team at Oasmia Pharmaceutical AB. It provides biographical information about the new CEO and quotes from the Chairman. This fits the definition of a Board/Management Information announcement. Although it mentions an attachment, the core content is the announcement of the management change itself, not merely a report publication notice.
2019-06-28 English
Oasmia announces change of CEO
Board/Management Information Classification · 100% confidence The document announces the appointment of a new CEO, Sven Rohmann, and details changes in the management team at Oasmia Pharmaceutical AB. It provides biographical information about the new CEO and quotes from the Chairman. This fits the definition of a Board/Management Information announcement. Although it mentions an attachment, the core content is the announcement of the management change itself, not merely a report publication notice.
2019-06-28 English
The Board of Oasmia has decided to report certain transactions to the Swedish Economic Crime Authority and to appoint a special examiner
Legal Proceedings Report Classification · 95% confidence The document details the company's decision to report suspicious transactions to the Swedish Economic Crime Authority following a tax audit. It discusses legal and regulatory investigations into past transactions involving former executives. While it mentions an upcoming AGM, the primary purpose of the text is to disclose significant legal and regulatory developments, which falls under the category of legal proceedings or regulatory announcements. Given the nature of the disclosure regarding potential criminal activity and regulatory reporting, 'LTR' (Legal Proceedings Report) is the most accurate classification.
2019-06-28 English
The Board of Oasmia has decided to report certain transactions to the Swedish Economic Crime Authority and to appoint a special examiner
Legal Proceedings Report Classification · 95% confidence The document details the company's decision to report suspicious transactions to the Swedish Economic Crime Authority following a tax audit. It discusses legal and regulatory investigations into past transactions involving former executives. While it mentions an upcoming AGM, the primary purpose of the text is to disclose significant legal and regulatory developments, which falls under the category of legal proceedings or regulatory announcements. Given the nature of the disclosure regarding potential criminal activity and regulatory reporting, 'LTR' (Legal Proceedings Report) is the most accurate classification.
2019-06-28 English
The Board of Oasmia has decided to report certain transactions to the Swedish Economic Crime Authority and to appoint a special examiner
Legal Proceedings Report Classification · 95% confidence The document details the company's decision to report suspicious transactions to the Swedish Economic Crime Authority following a tax audit. It discusses legal and regulatory investigations into past transactions involving former executives. While it mentions an upcoming AGM, the primary purpose of the text is to disclose significant legal and regulatory developments, which falls under the category of legal proceedings or regulatory announcements. Given the nature of the disclosure regarding potential criminal activity and regulatory reporting, 'LTR' (Legal Proceedings Report) is the most accurate classification.
2019-06-28 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.